Endothelin ET(A) receptor antagonist reverses the inhibitory effect of platelet-derived growth factor on cytokine-induced nitric oxide production

Junichi Hirahashi, Toshio Nakaki, Keiichi Hishikawa, Takeshi Marumo, Matsuhiko Hayashi, Takao Saruta

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cytokines and cytokine-induced nitric oxide (NO) play important roles in inflammatory glomerular diseases, and both platelet-derived growth factor and transforming growth factor-β inhibit cytokine-induced NO production. In this study, we demonstrated that a selective endothelin ET(A) receptor antagonist, BQ-485 (Hexahydro-1H-azepinylcarbonyl-Leu-d-Trp-d-Trp-OH), reversed the inhibitory effect of platelet-derived growth factor on cytokine-induced NO production, but not that of transforming growth factor-β. Our findings suggest a difference between the inhibitory mechanisms of platelet-derived growth factor and transforming growth factor-β on cytokine-induced NO production. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)119-123
Number of pages5
JournalEuropean journal of pharmacology
Volume365
Issue number1
DOIs
Publication statusPublished - 1999 Jan 15

Keywords

  • Endothelin ET(A) receptor
  • Mesangial cells
  • Nitric oxide (NO)
  • Platelet-derived growth factor
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Endothelin ET(A) receptor antagonist reverses the inhibitory effect of platelet-derived growth factor on cytokine-induced nitric oxide production'. Together they form a unique fingerprint.

  • Cite this